Kevin Blyth, MBChB, MD, FRCP, University of Glasgow, Glasgow, UK, reflects on the evolving treatment landscape of mesothelioma, highlighting combination immunotherapy as the new standard of care for this patient population. Dr Blyth also touches on current unmet needs such as therapeutic approaches for patients who do not respond to checkpoint inhibition, as well as optimal management of early-stage mesothelioma which is becoming of increased importance due to improvements in the diagnostic pathway. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть